Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
NIH-supported study demonstrates that turning off the prion protein gene can dramatically reduce toxic build-up, offering hope for …
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
A new framework aims to harmonize clinical trial data reporting across borders, boosting transparency and accelerating global drug …
FDA mandates clearer drug ads, Merck expands oncology portfolio, and political shifts raise questions about public health leadership.
The CGM giant and smart ring innovator join forces to integrate biosensor data and reshape personal health tracking.
Amgen’s MariTide leads the pack, while other candidates face setbacks in the competitive GLP-1RA landscape.
Already a subscriber? Log in